Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.58 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089620 | 0.82 | RAB9A (0.70) | NPC1RAB9ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL5097531 | 0.80 | IRAK4 (0.69) | IRAK4IRAK1ALDH1A1KDM4ERXFP1 | |
| SCHEMBL6258346 | 0.78 | ALDH1A1 (0.52) | IRAK4IRAK1MAP3K7NPC1RAB9A | |
| SCHEMBL28652762 | 0.76 | ALDH1A1 (0.53) | IRAK4IRAK1MAP3K7NPC1RAB9A | |
| SCHEMBL29313498 | 0.75 | EGFR (0.53) | IRAK4IRAK1MAP3K7NPC1RAB9A | |
| SCHEMBL16755391 | 0.74 | EGFR (0.61) | NPC1RAB9ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL1923996 | 0.74 | IRAK4 (1.00) | IRAK4IRAK1MAP3K7 | |
| SCHEMBL11707540 | 0.73 | RAB9A (0.69) | NPC1RAB9ATP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL21025638 | 0.73 | MAP3K7 (0.69) | IRAK4IRAK1MAP3K7ALDH1A1MAPT | |
| SCHEMBL16755407 | 0.73 | EGFR (0.53) | NPC1RAB9ATP53ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338956-B2 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-04 | — | — | US | disclosed |
| EP-1534275-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014369-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388341-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | EDNRA, LIPG, CYP11B1 | IRAK4 2523/4885IRAK1 2469/4885MAP3K7 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.